ALAlphabet Inc.

Institutional investor · Portfolio as of Q4 2025

SEC EDGAR SourceSEC Filings

Top Holdings29 positions

Checking export access…
Activity:
Stock
Shares
Value
Weight
Avg Buy
Est. P&L
Held
Conviction

AST SPACEMOBILE INC

8.9M$649.6M25.2%$24.06+210.39%
4 qtrssince 2025-Q1
Unchanged
0

PLANET LABS PBC

31.9M$629.9M24.4%$4.35+353.79%
13 qtrssince 2022-Q4
Unchanged
0

REVOLUTION MEDICINES INC

3.3M$266.4M10.3%$28.69+177.69%
9 qtrssince 2023-Q4
Decreased
0
ARMARM
ADR

ARM Holdings PLC Sponsored ADR

2M$214.3M8.3%$53.52+107.14%
10 qtrssince 2023-Q3
Unchanged
0

FRESHWORKS INC

16.2M$198.5M7.7%$15.72-21.57%
13 qtrssince 2022-Q4
Unchanged
0

UIPATH INC

7M$115.3M4.5%$12.71+31.16%
13 qtrssince 2022-Q4
Unchanged
0

GITLAB INC

2.7M$102.3M4.0%$54.31-29.73%
13 qtrssince 2022-Q4
Unchanged
0

Tempus AI, Inc. Class A

1.6M$91.6M3.6%$35.00+72.54%
7 qtrssince 2024-Q2
Unchanged
0

DEXCOM INC

1M$68.8M2.7%$122.16-27.34%
13 qtrssince 2022-Q4
Unchanged
0

MAZE THERAPEUTICS INC

1.4M$57.5M2.2%$11.42+250.70%
4 qtrssince 2025-Q1
Decreased
0

PRIME MEDICINE INC

16.6M$57.5M2.2%$15.14-77.28%
13 qtrssince 2022-Q4
Unchanged
0

BRIDGEBIO ONCOLOGY THERAPEUT

2.8M$35.3M1.4%$11.47+7.85%
2 qtrssince 2025-Q3
Unchanged
0

RELAY THERAPEUTICS INC

1.6M$13.3M0.5%$14.94-44.11%
13 qtrssince 2022-Q4
Unchanged
0

VERA THERAPEUTICS INC

241,264$12.2M0.5%$19.35+164.44%
13 qtrssince 2022-Q4
Unchanged
0

MONTE ROSA THERAPEUTICS INC

744,948$11.7M0.5%$7.61+109.86%
13 qtrssince 2022-Q4
Decreased
0

SANA BIOTECHNOLOGY INC

2.8M$11.4M0.4%$3.95+3.29%
13 qtrssince 2022-Q4
Unchanged
0

LYELL IMMUNOPHARMA INC

293,256$9M0.3%$69.40-54.48%
13 qtrssince 2022-Q4
Unchanged
0

BEAM THERAPEUTICS INC

321,604$8.9M0.3%$39.11-28.87%
13 qtrssince 2022-Q4
Unchanged
0

FIGMA INC-CL A

215,582$8.1M0.3%$53.15-29.20%
2 qtrssince 2025-Q3
Unchanged
0

OSCAR HEALTH INC - CLASS A

481,988$6.9M0.3%$2.46+489.84%
13 qtrssince 2022-Q4
Unchanged
0
$2.6B
AUM
29
Positions
Q4 2025
Filing
Rating · 1.5
Quarterly Portfolio Change
-7%Q3'24$1.8B-7%Q4'24$1.7B-8%Q1'25$1.6B+35%Q2'25$2.1B+13%Q3'25$2.4B+7%Q4'25$2.6B
Activity profile
$ moved · Q4'25
New0%Increased0%Decreased27%Exited73%
Composition
Equity vs derivatives
Equity100%Puts0%Calls0%
Holding period
Avg 2.5 years
<1Q0%1-4Q14%1-2Y7%2Y+79%

Alphabet Inc. manages $2.6B across 29 positions as of Q4 2025. Top holdings: ASTS (25.2%), PL (24.4%), RVMD (10.3%). Fund DNA: Concentrated Value. HoldingsIntel Rating: 1.5/5.0.

Q4 2025 Summary

Active quarter - 0 new positions, 8 exits, 0 increased. No standout high-conviction moves this quarter. Portfolio: $2.6B across 29 positions.

Top holdings by portfolio weight

Total AUM$3B
ASTS25.18%
PL24.42%
RVMD10.33%
ARM8.31%
FRSH7.70%
PATH4.47%
GTLB3.96%
TEM3.55%
DXCM2.67%
MAZE2.23%
Other2.23%

Portfolio allocation by GICS sector

Sectors3
Technology49.93%
Healthcare25.65%
Industrials24.42%

Behavioral investing profile

Checking access…
Concentrated Value- primarily Technology, Healthcare, Industrials
Compare DNA across all funds
7-dimension quality assessment
Below Average(1.5 / 5.0)
Track RecordNo data
Conviction37
Concentration100
Checking access…

Position Outcomes

Best and worst performing positions by estimated return

Cost basis estimates based on full filing history using quarter-end prices. Actual transaction prices are not disclosed in 13F filings.

Similar Funds

Funds with similar investing DNA

Accumulation Streaks

Positions with 2+ consecutive quarters of increases - persistent directional conviction.

No active accumulation streaks detected for this filer.

Streaks require 2+ consecutive quarters of increased positions in the most recent period.

Data sourced from SEC EDGAR 13F filings. Not financial advice. Full disclaimer

Analytics tracking helps us improve the product. Essential functions stay on either way. How analytics data is used